Material Event (Form 8-K)

On April 1, 2026 Inovio Pharmaceuticals, Inc. (the "Company") notified Oppenheimer & Co. Inc. (the "Sales Agent") that it was suspending and terminating the prospectus, dated August 13, 2024 (the "ATM Prospectus"), related to the sales agreement (the "Sales Agreement") that the Company entered into with the Sales Agent on August 13, 2024 and pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the "Common Stock"), through the Sales Agent. The Company will not make any sales of its Common Stock pursuant to the Sales Agreement unless and until a new prospectus is filed. The Sales Agreement remains in full force and effect. As of April 1, 2026, the Company had issued and sold an aggregate of 1,319,644 shares of its Common Stock under its "at-the-market"offering program with the Sales Agent for aggregate gross sale proceeds of $3.2 million, before deducting sales commissions and offering expenses.

A copy of the Sales Agreement was filed as Exhibit 1.1 to the Company's Current Report on Form 8-K (001-14888),which was originally filed with the Securities and Exchange Commission on August 13, 2024.